EJPMR, 2026, 13(4), 77-83 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

ROLE OF ANTIPLATELET AGENTS IN THROMBOSIS: A REVIEW

[1]Mr. Nishant Sarode, *Dr. Ankitkumar Merai

[1]Research Scholar, Rajju Shroff Rofel University, Vapi.
*Professor, Dept. of Pharmacology, ROFEL Shri. Bilakhia College of Pharmacy, Rajju Shroff Rofel University.

***Corresponding Author: Dr. Ankitkumar Merai**

Professor, Dept. of Pharmacology, ROFEL Shri. Bilakhia College of Pharmacy, Rajju Shroff Rofel University.

DOI: https://doi.org/10.5281/zenodo.19326434

How to cite this Article: [1]Mr. Nishant Sarode, *Dr. Ankitkumar Merai. (2026). Role of Antiplatelet Agents In Thrombosis: A Review. European Journal of Pharmaceutical and Medical Research, 13(4), 77–83.

Article Received on 25/02/2026 **Article Revised on 17/03/2026** **Article Published on 01/04/2026**

ABSTRACT

Thrombosis is a major global health concern and a leading cause of morbidity and mortality, particularly in cardiovascular and cerebrovascular diseases such as myocardial infarction, ischemic stroke, deep vein thrombosis, and peripheral arterial disease. Arterial thrombi are primarily platelet-rich and form through mechanisms described by Virchow's triad: endothelial injury, abnormal blood flow, and hypercoagulable states. Platelets contribute to thrombus formation via adhesion, activation, and aggregation, mediated by glycoprotein receptors and prothrombotic mediators like thromboxane A_2 and adenosine diphosphate. Antiplatelet agents—including cyclooxygenase inhibitors, $P2Y_{12}$ receptor antagonists, glycoprotein IIb/IIIa inhibitors, phosphodiesterase inhibitors, thrombin receptor antagonists, prostacyclin analogues, and thromboxane-targeted drugs—suppress platelet function at multiple points and are central to managing arterial thrombosis. Clinically, these drugs are used in acute coronary syndromes, post-percutaneous coronary interventions, secondary stroke prevention, and peripheral arterial disease, often in combination as dual therapy for high-risk patients. Formulation strategies, such as enteric coating, modified-release systems, pro-drug design, and novel delivery methods, improve efficacy, safety, and adherence. Despite their benefits, antiplatelet therapies carry risks of bleeding, gastrointestinal effects, and variable patient response, emphasizing the need for careful management and ongoing development of safer, more targeted treatments.

KEYWORDS: Thrombosis, Platelets, Antiplatelet Therapy, Arterial Thrombosis, Drug Formulation.

1. INTRODUCTION[1-7]

Thrombosis is a major global health concern and a leading cause of morbidity and mortality, particularly in cardiovascular and cerebrovascular diseases. It is the underlying pathological process in life-threatening conditions such as myocardial infarction, ischemic stroke, deep vein thrombosis, and peripheral arterial disease. The formation of an intravascular thrombus can obstruct blood flow, resulting in tissue ischemia, organ dysfunction, and, in severe cases, death. With the rising prevalence of risk factors such as aging, diabetes, hypertension, smoking, and sedentary lifestyles, the burden of thrombotic disorders continues to increase worldwide.

The pathogenesis of thrombosis is classically explained by Virchow's triad, which comprises endothelial injury, abnormal blood flow (stasis or turbulence), and hypercoagulability. Endothelial damage exposes subendothelial collagen and tissue factors that promote platelet adhesion and activation. Disturbances in blood flow enhance platelet–vessel wall interactions, while hypercoagulable states increase the tendency for clot formation. These factors act synergistically to disrupt normal hemostatic balance, favoring pathological thrombus development.



Figure 1: Virchow's triad.

In arterial thrombosis, platelet activation and aggregation play a predominant role due to the high-shear conditions of arterial blood flow. Activated platelets release prothrombotic mediators such as thromboxane A_2 and adenosine diphosphate, which amplify platelet recruitment and thrombus growth. Consequently, inhibition of platelet function has become a central strategy in the prevention and treatment of arterial thrombotic events. Antiplatelet agents therefore represent a cornerstone of therapy in conditions such as acute coronary syndromes, stroke prevention, and post-interventional cardiovascular care.

2. Role of Platelets in Thrombosis[5-14]

Platelets are small, anucleate cell fragments derived from megakaryocytes in the bone marrow and play a crucial role in primary hemostasis. Under normal physiological conditions, they help maintain vascular integrity by forming a temporary hemostatic plug at sites of vessel injury. However, in pathological states, excessive or inappropriate platelet activation contributes significantly to thrombus formation. Platelets rapidly respond to endothelial damage and circulating agonists, making them central mediators in the development of arterial thrombosis.

The involvement of platelets in thrombosis occurs through a well-coordinated sequence of events, namely adhesion, activation, and aggregation. Following vascular injury, platelets adhere to exposed subendothelial collagen through interactions between von Willebrand factor and platelet glycoprotein receptors, particularly the GP Ib/IX/V complex. This adhesion initiates platelet activation, resulting in cytoskeletal rearrangement, shape change, and the release of prothrombotic mediators such as adenosine diphosphate (ADP), thromboxane A_2 (TXA_2), and serotonin. These mediators amplify platelet activation and recruit additional platelets to the site of injury.

Activated platelets express glycoprotein IIb/IIIa receptors on their surface, which serve as the final common pathway for platelet aggregation. Binding of fibrinogen to these receptors links platelets together, forming a stable platelet plug that contributes to thrombus growth. In arterial circulation, where blood flow is rapid and shear stress is high, platelet-rich thrombi, also known as "white thrombi," predominate. This platelet-driven nature of arterial thrombosis underscores the critical role of antiplatelet agents in preventing and managing thrombotic disorders.

3. Antiplatelet Agents: Classification and Mechanism of Action[15-24]

Antiplatelet agents are drugs that inhibit platelet activation and aggregation, which are crucial steps in the formation of arterial thrombi. They are widely used in the prevention and management of cardiovascular and cerebrovascular disorders such as myocardial infarction, ischemic stroke, and peripheral arterial disease. These agents act at different stages of platelet activation pathways, thereby reducing thrombus formation without directly affecting the coagulation cascade.

Cyclooxygenase (COX) Inhibitors

Aspirin is the prototype and most commonly used cyclooxygenase inhibitor. It exerts its antiplatelet effect by irreversibly inhibiting the COX-1 enzyme in platelets. This inhibition prevents the conversion of arachidonic acid into prostaglandin H_2, leading to a marked reduction in the synthesis of thromboxane A_2 (TXA_2), a potent promoter of platelet aggregation and vasoconstriction. Because platelets lack a nucleus, they cannot synthesize new COX-1 enzymes; therefore, the antiplatelet effect of aspirin persists for the entire lifespan of the platelet, approximately 7–10 days. At low doses, aspirin selectively inhibits platelet COX-1 while sparing endothelial prostacyclin production, enhancing its antithrombotic efficacy.

ADP ($P2Y_{12}$) Receptor Inhibitors

ADP receptor inhibitors interfere with platelet activation by blocking the $P2Y_{12}$ receptor, which plays a central role in amplifying platelet aggregation and stabilizing the platelet plug. This receptor is responsible for ADP-mediated activation of the glycoprotein IIb/IIIa complex, a key step in platelet aggregation.

- Clopidogrel and prasugrel are prodrugs that require hepatic activation and irreversibly inhibit the $P2Y_{12}$ receptor.
- Ticagrelor is a direct-acting, reversible $P2Y_{12}$ inhibitor with a faster onset of action.
- Ticlopidine, an older agent, is less commonly used due to adverse effects such as neutropenia and thrombotic thrombocytopenic purpura.

By blocking ADP signaling, these drugs effectively reduce platelet activation, aggregation, and thrombus formation, especially in patients with acute coronary syndromes and those undergoing percutaneous coronary interventions.

Glycoprotein IIb/IIIa Inhibitors

Glycoprotein IIb/IIIa inhibitors target the final common pathway of platelet aggregation. The GP IIb/IIIa receptor, present on the platelet surface, mediates platelet-to-platelet binding by allowing fibrinogen and von Willebrand factor to cross-link activated platelets.

- Abciximab is a monoclonal antibody that irreversibly blocks the receptor.
- Eptifibatide and tirofiban are synthetic, reversible inhibitors.

By preventing fibrinogen binding, these agents produce profound inhibition of platelet aggregation. They are primarily used intravenously in high-risk settings such as acute coronary syndromes and during coronary angioplasty.

Phosphodiesterase (PDE) Inhibitors

Phosphodiesterase inhibitors, such as dipyridamole and cilostazol, exert their antiplatelet effect by increasing intracellular levels of cyclic adenosine monophosphate (cAMP) within platelets. Elevated cAMP inhibits platelet activation and aggregation by reducing calcium mobilization.

- Dipyridamole also inhibits adenosine uptake, further enhancing its antiplatelet action.
- Cilostazol additionally causes vasodilation and is particularly useful in patients with intermittent claudication.

These agents are often used in combination with other antiplatelet drugs rather than as monotherapy.

Thrombin Receptor (PAR-1) Antagonists

Vorapaxar is a selective antagonist of the protease-activated receptor-1 (PAR-1), the primary receptor through which thrombin activates platelets. By blocking PAR-1, vorapaxar inhibits thrombin-induced platelet activation without interfering with thrombin's role in the coagulation cascade. This allows effective suppression of platelet aggregation while preserving normal clotting mechanisms. Vorapaxar is mainly used for secondary prevention in patients with a history of myocardial infarction or peripheral arterial disease, although its use is limited by an increased risk of bleeding.

Table 1: Classes of Antiplatelet Agents and Their Mechanisms.

Class	Examples	Mechanism of Action
COX-1 Inhibitors	Aspirin	Irreversibly inhibits cyclooxygenase-1 (COX-1), reducing synthesis of thromboxane A_2 (TXA_2), a key mediator of platelet aggregation and vasoconstriction.
$P2Y_{12}$ (ADP) Receptor Antagonists	Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine	Block the $P2Y_{12}$ ADP receptor on platelets, inhibiting ADP-mediated platelet activation and preventing sustained aggregation.
GPIIb/IIIa Inhibitors	Abciximab, Eptifibatide, Tirofiban	Inhibit the glycoprotein IIb/IIIa receptor, preventing fibrinogen binding and blocking the final common pathway of platelet aggregation.
Phosphodiesterase (PDE) Inhibitors	Dipyridamole, Cilostazol	Inhibit phosphodiesterase, leading to increased intracellular cAMP, which suppresses platelet activation and aggregation.
Thrombin Receptor (PAR-1) Antagonists	Vorapaxar	Block protease-activated receptor-1 (PAR-1) on platelets, inhibiting thrombin-induced platelet activation without affecting coagulation factors.
Prostacyclin (PGI_2) Analogues	Epoprostenol, Iloprost	Mimic prostacyclin activity, increasing platelet cAMP levels, thereby inhibiting platelet aggregation and causing vasodilation.
Thromboxane A_2 Synthesis / Receptor Inhibitors	Ridogrel, Terutroban	Inhibit TXA_2 synthesis or block TXA_2 receptors, reducing platelet aggregation and vasoconstriction.
Adenosine Uptake Inhibitors	Dipyridamole	Inhibit adenosine reuptake, increasing extracellular adenosine and intracellular cAMP, leading to reduced platelet activation.

4. Clinical Role of Antiplatelet Agents in Thrombosis[25-32]

Antiplatelet agents play a central role in the prevention and management of arterial thrombosis, which is predominantly platelet-rich due to high shear stress and endothelial injury. Unlike venous thrombosis, which is mainly fibrin-driven, arterial thrombi are largely mediated by platelet activation and aggregation. By inhibiting key pathways involved in platelet function,

antiplatelet drugs significantly reduce the risk of thrombus formation and subsequent ischemic events.

These agents are widely used in several major cardiovascular and cerebrovascular conditions, including:

Acute coronary syndromes (ACS): Antiplatelet therapy is essential in unstable angina and myocardial infarction, where plaque rupture leads to platelet activation and arterial occlusion. Early and sustained antiplatelet use reduces infarct size, prevents reinfarction, and improves survival.

Post-percutaneous coronary intervention (PCI): Following coronary stent placement, antiplatelet agents prevent stent thrombosis by inhibiting platelet adhesion and aggregation on the stent surface.

Secondary prevention of ischemic stroke and transient ischemic attack (TIA): Antiplatelet drugs reduce the risk of recurrent cerebrovascular events by preventing platelet-mediated thrombus formation in cerebral arteries.

Peripheral arterial disease (PAD): These agents decrease the risk of limb ischemia and major cardiovascular events by improving arterial blood flow and reducing thrombotic complications.

Dual antiplatelet therapy (DAPT), most commonly a combination of aspirin and a $P2Y_{12}$ receptor inhibitor such as clopidogrel, prasugrel, or ticagrelor, is considered the standard of care in high-risk cardiovascular patients. DAPT provides synergistic inhibition of platelet activation by targeting multiple pathways, thereby offering superior protection against thrombotic events compared to monotherapy. However, its use requires careful balancing of antithrombotic benefits against the increased risk of bleeding, and treatment duration is tailored based on individual patient risk profiles.

5. Formulation Aspects of Antiplatelet Agents[33-42]

The formulation of antiplatelet agents plays a critical role in ensuring their therapeutic efficacy, stability, safety, and patient adherence. Since these drugs are often used for long-term or lifelong therapy, careful consideration is given to dosage form selection, bioavailability enhancement, protection from degradation, and minimization of adverse effects, particularly gastrointestinal irritation and bleeding risk.

Dosage Forms

Most antiplatelet agents are formulated as oral solid dosage forms, such as tablets and capsules, due to their convenience, stability, and suitability for chronic administration. Oral formulations allow for precise dosing and ease of patient compliance. In contrast, parenteral formulations are primarily reserved for glycoprotein IIb/IIIa inhibitors, which are administered intravenously in acute care settings such as intensive care units. These injectable formulations enable rapid onset of action and tight clinical control in high-risk patients.

Bioavailability and Drug Stability

Bioavailability and chemical stability are major formulation challenges for several antiplatelet agents. For instance, Aspirin is chemically unstable and readily undergoes hydrolysis to salicylic acid and acetic acid, particularly in the presence of moisture. To maintain potency, formulations require moisture-resistant packaging, protective coatings, and the use of suitable excipients that minimize degradation.

Clopidogrel exhibits low aqueous solubility and is sensitive to both light and moisture, which can compromise its stability. As a result, formulation strategies include protective film coatings, use of stabilizing excipients, and optimized blister packaging to ensure adequate shelf life and consistent therapeutic performance.

Modified and Targeted Release Formulations

Modified-release formulations are designed to improve tolerability, maintain steady plasma drug concentrations, and enhance patient compliance.

Enteric-coated aspirin delays drug release until it reaches the intestine, thereby reducing direct gastric mucosal irritation while preserving its systemic antiplatelet effect.

Sustained-release formulations of dipyridamole prolong drug release over time, reducing dosing frequency and maintaining therapeutic plasma levels, which is particularly beneficial in long-term secondary prevention of stroke.

Such formulations are especially important for patients requiring chronic therapy.

Prodrug Considerations

Certain antiplatelet agents, notably clopidogrel and prasugrel, are administered as prodrugs that require hepatic biotransformation to produce their active metabolites. From a formulation perspective, it is essential to ensure consistent and predictable absorption, as variability in dissolution or bioavailability can lead to interpatient differences in therapeutic response. Optimized formulation design helps minimize variability related to gastrointestinal transit time and absorption, thereby improving clinical reliability.

Combination Products

Fixed-dose combination products, such as aspirin combined with clopidogrel, are increasingly used to enhance patient adherence by reducing pill burden. While these combinations offer therapeutic convenience, they present formulation challenges, including:

- Potential chemical incompatibility between active ingredients
- Risk of dose dumping in modified-release systems
- Need for synchronized release profiles to maintain optimal antiplatelet effects
- Careful selection of excipients, coating strategies, and manufacturing processes is required to ensure product stability and safety.

Novel Drug Delivery Systems

Advanced drug delivery systems are being explored to overcome limitations associated with conventional formulations. Emerging approaches include nanoparticle-based delivery systems, liposomes, and polymeric carriers, which aim to:

- Improve drug bioavailability
- Reduce systemic bleeding risk
- Enable targeted delivery to thrombus sites
- Enhance therapeutic efficacy while minimizing adverse effects
- These innovative systems represent promising future strategies for optimizing antiplatelet therapy, particularly in high-risk patient populations.

6. Limitations and Safety Considerations[43-52]

Despite their proven clinical benefits, antiplatelet agents are associated with several important limitations and safety concerns that must be carefully considered during therapy. The most significant adverse effect common to all antiplatelet drugs is bleeding, which may range from minor bruising to severe, life-threatening hemorrhage, particularly with long-term use or combination therapy such as dual antiplatelet therapy. The risk of bleeding increases in elderly patients, those with renal or hepatic impairment, and individuals receiving concurrent anticoagulant or nonsteroidal anti-inflammatory drugs.

Gastrointestinal irritation is another major limitation, especially with aspirin, due to its direct mucosal irritant effect and inhibition of protective prostaglandin synthesis in the gastric lining. This may lead to dyspepsia, gastric erosions, or peptic ulcer disease. Additionally, certain antiplatelet agents exhibit interindividual variability in therapeutic response, often attributed to genetic polymorphisms affecting drug metabolism. For example, variations in hepatic enzymes can influence the activation and efficacy of prodrug agents such as clopidogrel, resulting in reduced antiplatelet activity in some patients.

Formulation strategies play a critical role in mitigating these safety concerns. Approaches such as enteric coating, modified-release systems, protective excipients, and optimized combination formulations help reduce gastrointestinal toxicity, improve drug stability, and ensure more consistent bioavailability. Furthermore, emerging drug delivery systems aim to enhance targeted action while minimizing systemic exposure, thereby improving the overall safety profile of antiplatelet therapy.

7. CONCLUSION

Antiplatelet agents are vital in the management of arterial thrombosis due to their ability to inhibit platelet activation and aggregation. Advances in pharmaceutical formulation have significantly improved their safety, efficacy, and patient compliance. Ongoing research into novel delivery systems and combination therapies continues to enhance their therapeutic potential in thrombotic disorders.

8. BIBLIOGRAPHY

1. Cate H. Thrombosis: Grand Challenges Ahead! Front Cardiovasc Med., 2021; 8: 637005.
2. Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, Naidu S, Oklu R. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther., Dec. 2017; 7(3): S276–84.
3. Kushner A, West WP, Khan SM, et al. Virchow Triad. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539697/.
4. Thrombus. In: Wikipedia. Available from: https://en.wikipedia.org/wiki/Thrombus.
5. Platelets and cardiovascular risk. Platelets Cardiovasc Risk. 2017; Review.
6. Mechanisms of Platelet Activation in Thromboembolic Disorders. J Thrombo Cir., 2024; 10: 271.
7. Michelson AD. Platelets and Their Role in Hemostasis and Thrombosis—From Physiology to Pathophysiology and Therapeutic Implications. Int J Mol Sci., 2022; 23(21): 12772.
8. Ruggeri ZM. Platelet adhesion in arterial thrombosis. J Clin Invest, 2002; 109(3): 335–342.
9. Jackson SP, Schoenwaelder SM. Platelet adhesion receptors and (patho) physiological thrombus formation. Thromb Haemost, 2001; 86(1): 149–154.
10. Goto S, et al. Platelet adhesion and activation mechanisms in arterial thrombosis. J Thromb Haemost, 2011; 9(2): 228–239.
11. Andrews RK, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion. Blood, 2004; 104(4): 953–961.
12. Varga-Szabo D, et al. Platelet adhesion and aggregation: The interplay of receptors and ligands. Circ J., 2010; 74(4): 598–607.
13. Walther A, et al. Mechanisms of platelet activation in thromboembolic disorders. Walsh Med Media, 2024; 129797.
14. Westphal K, et al. Platelet plug formation and GPIIb/IIIa receptor role in aggregation. Platelet plug. Wikipedia, 2025.
15. Bhatt DL, Topol EJ. Antiplatelet therapy: Aspirin and beyond. Nat Rev Drug Discov, 2003; 2(12): 939–951.
16. Yusuf S, et al. Effects of antiplatelet therapy on mortality and cardiovascular outcomes. Lancet, 2005; 365(9454): 349–360.

17. StatPearls. Antiplatelet Medications. 2026 Jan – StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537062/
18. Pharmacology Mentor. Pharmacology of Antiplatelet Drugs. Available from: https://pharmacologymentor.com/pharmacology-of-antiplatelet-drugs/
19. Pharmacology Education Project. Antiplatelet Drugs Classification. Available from: https://www.pharmacologyeducation.org/antiplatelet-drugs
20. Sumathi Publications. Classification of Antiplatelet Drugs and their Clinical Uses. Available from: https://journals.sumathipublications.com/classification-of-antiplatelet-drugs-and-their-clinical-uses/
21. ScienceDirect Topics. Antiplatelet – Glycoprotein IIb/IIIa Inhibitors. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/antiplatelet
22. CICM Wrecks. Antiplatelet Agents – Pharmacology. Available from: https://cicmwrecks.com/topics/q/q02/
23. International Journal of Pharmacy and Pharmaceutical Science. Drugs Used in Antiplatelet Therapy for Cardiovascular Diseases, 2025; 7(2): 313–322.
24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med., 2001; 345(7): 494–502.
25. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: results of the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. Circulation, 2002; 106(10): 1216–1222.
26. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014; 45(7): 2160–2236.
27. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med., 2006; 354(16): 1706–1717.
28. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol, 2016; 67(10): 1235–1250.
29. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article. J Am Coll Cardiol, 2006; 47(1): 216–235.
30. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med., 2006; 355(6): 549–559.
31. Baumgartner I, Badorff C, Bax J, et al. ESVS guidelines on the management of atherosclerotic peripheral arterial disease. Eur J Vasc Endovasc Surg, 2017; 53(4): 460–510. doi:10.1016/j.ejvs.2016.10.020.
32. Valgimigli M, Teng R, Campo G, et al. Ischaemic and bleeding outcomes with ticagrelor compared with clopidogrel in patients after percutaneous coronary intervention: results from the PEGASUS-TIMI 54 trial. Lancet, 2016; 387(10013): 2371–2379.
33. Chou TC. Antiplatelet agents: Pharmacodynamics, clinical pharmacology, formulations, and adverse effects. Cardiovasc Drug Rev., 2002; 20(1): 55–83.
34. Sundrarajan S, et al. Formulation strategies to improve the stability and bioavailability of aspirin. Int J Pharm Sci Rev Res., 2019; 56(1): 150–159.
35. Patel VB, Ashraf M. Pharmaceutical issues in the formulation of antiplatelet prodrugs: Focus on clopidogrel and prasugrel. Drug Dev Ind Pharm., 2016; 42(5): 701–710.
36. Kumar S, Garg A. Modified release drug delivery systems for antiplatelet therapy. Asian J Pharm Sci., 2017; 12(4): 360–373.
37. Sawant KK, et al. Sustained release dipyridamole formulation for enhanced patient compliance: Design, characterization and evaluation. Drug Deliv, 2015; 22(6): 759–768.
38. Tiwari G, et al. Nano-carrier based approaches for enhancing bioavailability and efficacy of antithrombotic agents. J Nanobiotechnology, 2021; 19(1): 110.
39. Patel MM, Patel BN. Enteric coating technology: Mechanisms, materials, and quality control. Pharm Dev Technol, 2018; 23(5): 457–469.
40. Wang J, et al. Complex formulation challenges in fixed-dose combination antiplatelet products. Int J Pharm., 2018; 547(1–2): 577–589.
41. Chien YW. Novel delivery systems for cardiovascular drugs: Focus on liposomes and polymeric carriers for antiplatelet agents. J Control Release, 2020; 321: 168–185.
42. El-Kasabgy NA, Abdel-Rahman SM. Enhancing stability of moisture-sensitive drugs: Challenges, protective coatings, and packaging strategies. Pharmaceutics, 2023; 15(2): 338.
43. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med., 2005; 353(22): 2373–2383.
44. Hennekens CH, DeMets DL. Aspirin and gastrointestinal bleeding: recommendations for clinicians and patients. JAMA, 1999; 281(13): 1182–1183.

45. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med., 2009; 360(4): 354–362. doi:10.1056/NEJMoa0809171
46. Gaziano TA, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, 2018; 392(10152): 1036–1046.
47. Cheung KS, Leung WK. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. World J Gastroenterol, 2006; 12(36): 5751–5756.
48. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2010 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol, 2010; 56(18): 1502–1517.
49. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol, 2007; 49(14): 1505–1516.
50. Forman DE, Hernandez AF. Bleeding risk with antiplatelet therapy: clinical predictors and risk scores. Am Heart J., 2011; 161(4): 637–644.
51. Tripathi KD. Essentials of Medical Pharmacology. 8th Ed. New Delhi: Jaypee Brothers Medical Publishers, 2019; 817–820.
52. Taha MO, Elmowafy M, Nasr M, et al. Formulation strategies to improve gastrointestinal safety and bioavailability of antiplatelet drugs. Pharmaceutics, 2021; 13(5): 724.